X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (392) 392
oncology (361) 361
chemotherapy (255) 255
index medicus (249) 249
female (214) 214
single-agent (187) 187
antineoplastic combined chemotherapy protocols - therapeutic use (185) 185
male (172) 172
aged (168) 168
middle aged (154) 154
carboplatin (143) 143
cancer (141) 141
lung neoplasms - drug therapy (136) 136
carcinoma, non-small-cell lung - drug therapy (132) 132
treatment outcome (131) 131
adult (125) 125
cisplatin (113) 113
neoplasm staging (106) 106
single-agent carboplatin (104) 104
antineoplastic agents - therapeutic use (99) 99
randomized-trial (95) 95
phase-ii trial (94) 94
paclitaxel (92) 92
gemcitabine (89) 89
deoxycytidine - analogs & derivatives (82) 82
carboplatin - administration & dosage (80) 80
lung neoplasms - pathology (78) 78
care and treatment (75) 75
antineoplastic combined chemotherapy protocols - adverse effects (72) 72
prognosis (72) 72
combination chemotherapy (68) 68
deoxycytidine - administration & dosage (68) 68
carcinoma, non-small-cell lung - pathology (67) 67
drug therapy (65) 65
disease-free survival (63) 63
research (63) 63
aged, 80 and over (61) 61
phase-iii trial (61) 61
paclitaxel - administration & dosage (60) 60
ovarian neoplasms - drug therapy (59) 59
survival analysis (58) 58
trial (58) 58
ovarian cancer (57) 57
hematology, oncology and palliative medicine (56) 56
lung cancer, non-small cell (55) 55
bevacizumab (54) 54
single-agent gemcitabine (54) 54
lung neoplasms - mortality (51) 51
pharmacology & pharmacy (51) 51
cisplatin - administration & dosage (50) 50
survival (50) 50
therapy (50) 50
vinorelbine (50) 50
combination (48) 48
docetaxel (48) 48
carcinoma, non-small-cell lung - mortality (47) 47
survival rate (47) 47
randomized controlled trials as topic (46) 46
quality-of-life (45) 45
cooperative-oncology-group (44) 44
1st-line treatment (43) 43
drug administration schedule (43) 43
platinum-based chemotherapy (43) 43
antineoplastic agents - adverse effects (42) 42
non-small cell lung cancer (42) 42
single-agent bevacizumab (42) 42
gynecologic-oncology-group (41) 41
health aspects (41) 41
neoplasm recurrence, local - drug therapy (41) 41
quality of life (41) 41
respiratory system (41) 41
carboplatin - adverse effects (40) 40
phase-ii (40) 40
radiotherapy (39) 39
carboplatin - therapeutic use (38) 38
carcinoma (38) 38
clinical trials as topic (38) 38
disease progression (38) 38
randomized phase-iii (37) 37
retrospective studies (37) 37
antineoplastic agents - administration & dosage (36) 36
clinical trials (36) 36
testicular neoplasms - pathology (36) 36
lung cancer (35) 35
antineoplastic combined chemotherapy protocols - administration & dosage (34) 34
single-agent paclitaxel (34) 34
combined modality therapy (33) 33
elderly-patients (33) 33
glioblastoma (33) 33
antineoplastic agents (32) 32
seminoma (32) 32
stage-iii (31) 31
antimitotic agents (30) 30
cancer therapies (30) 30
chemotherapy, adjuvant (30) 30
dose-response relationship, drug (30) 30
follow-up studies (30) 30
nsclc (30) 30
ovarian neoplasms - pathology (30) 30
drug resistance, neoplasm (29) 29
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 11/2009, Volume 27, Issue 33, pp. 5634 - 5639
Journal Article
Journal Article
Annals of Oncology, ISSN 0923-7534, 07/2011, Volume 22, Issue 7, pp. 1520 - 1527
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 06/2008, Volume 3, Issue 6, pp. 623 - 630
Journal Article
British Journal of Haematology, ISSN 0007-1048, 07/2014, Volume 166, Issue 1, pp. 77 - 83
Summary Relapsed/refractory diffuse large B‐cell lymphoma (DLBCL) is associated with a poor prognosis. Outcomes are particularly poor following... 
lenalidomide | diffuse large B‐cell lymphoma | salvage | rituximab | bone marrow transplantation | Bone marrow transplantation | Rituximab | Salvage | Lenalidomide | Diffuse large B-cell lymphoma | diffuse large B-cell lymphoma | COMBINATION | TRANSPLANTATION | TRIAL | SALVAGE TREATMENT | PLUS CYCLOPHOSPHAMIDE | ERA | NON-HODGKINS-LYMPHOMA | SINGLE-AGENT LENALIDOMIDE | HEMATOLOGY | PHASE-I | ELDERLY-PATIENTS | Recurrence | Salvage Therapy - adverse effects | Prognosis | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Carboplatin - adverse effects | Dose-Response Relationship, Drug | Thalidomide - analogs & derivatives | Bone Marrow Transplantation | Adult | Female | Thalidomide - adverse effects | Etoposide - adverse effects | Lymphoma, Large B-Cell, Diffuse - drug therapy | Lymphoma, Large B-Cell, Diffuse - pathology | Ifosfamide - adverse effects | Carboplatin - administration & dosage | Etoposide - administration & dosage | Treatment Outcome | Thalidomide - administration & dosage | Ifosfamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Neoplasm Staging | Antibodies, Monoclonal, Murine-Derived - adverse effects | Salvage Therapy - methods | Etoposide | Lymphomas | Stem cells | Index Medicus | Haematological Malignancy
Journal Article
Journal Article
Neuro-Oncology, ISSN 1522-8517, 11/2015, Volume 17, Issue 11, pp. 1504 - 1513
Journal Article
JOURNAL OF NEURO-ONCOLOGY, ISSN 0167-594X, 03/2012, Volume 107, Issue 1, pp. 155 - 164
We evaluated the efficacy of carboplatin, irinotecan, and bevacizumab among bevacizumab-na < ve, recurrent glioblastoma (GBM) patients in a phase 2,... 
VASCULAR NORMALIZATION | PLUS IRINOTECAN | PROGNOSTIC-FACTORS | Glioblastoma | INTRAVENOUS CARBOPLATIN | TUMOR ANGIOGENESIS | CLINICAL NEUROLOGY | Bevacizumab | MALIGNANT GLIOMA | TRIAL | Angiogenesis | Irinotecan | ANTIANGIOGENIC THERAPY | ONCOLOGY | SINGLE-AGENT BEVACIZUMAB | Carboplatin | Vascular endothelial growth factor | ENDOTHELIAL GROWTH-FACTOR
Journal Article
The European Journal of Health Economics, ISSN 1618-7598, 9/2016, Volume 17, Issue 7, pp. 855 - 863
Assess the cost-effectiveness of an EGFR-mutation testing strategy for advanced NSCLC in first-line therapy with either gefitinib or carboplatin–paclitaxel in... 
Health Economics | Economic Policy | Public Health | Carcinoma | Developing countries | I11 | Health Care Management | Non-small-cell lung | I18 | Pharmacoeconomics and Health Outcomes | Health policy | Medicine & Public Health | Public Finance & Economics | Mutation | Cost–benefit analysis | 1ST-LINE TREATMENT | TYROSINE KINASE | ADENOCARCINOMA | PHASE-III | ASIAN PATIENTS | OPEN-LABEL | CHEMOTHERAPY | Cost-benefit analysis | SINGLE-AGENT | HEALTH POLICY & SERVICES | ECONOMICS | ERLOTINIB | PREVIOUSLY TREATED PATIENTS | Lung Neoplasms - genetics | Quality-Adjusted Life Years | Lung Neoplasms - drug therapy | Models, Econometric | Protein Kinase Inhibitors - economics | Carcinoma, Non-Small-Cell Lung - genetics | Genes, erbB-1 - genetics | Humans | Male | Paclitaxel - therapeutic use | Latin America | Disease-Free Survival | Carboplatin - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Cost-Benefit Analysis | Antineoplastic Combined Chemotherapy Protocols - economics | Female | Mexico | Carcinoma, Non-Small-Cell Lung - drug therapy | Quinazolines - economics | Medical policy | Chemotherapy | Analysis | Cost benefit analysis | Lung cancer, Non-small cell | Gefitinib | Cancer | Health economics | Sensitivity analysis | Statistical analysis | Lung cancer | Health care policy | Patients | Cancer therapies | Developing countries--LDCs | Benefit cost analysis
Journal Article
Clinical Lung Cancer, ISSN 1525-7304, 2011, Volume 12, Issue 2, pp. 100 - 105
Journal Article
Veterinary and Comparative Oncology, ISSN 1476-5810, 06/2017, Volume 15, Issue 2, pp. 400 - 410
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 12/2012, Volume 30, Issue 36, pp. 4501 - 4507
Journal Article
Annals of Oncology, ISSN 0923-7534, 3/2010, Volume 21, Issue 3, pp. 540 - 547
Journal Article